Results 51 to 60 of about 23,382 (212)

LMNA-Cardiomyopathy in Emery-Dreifuss Muscular Dystrophy

open access: yesАрхивъ внутренней медицины
Emery-Dreifuss muscular dystrophy is a rare disease resulting from a genetic defect in nuclear envelope proteins, most commonly in emerin and lamin A/C.
E. V. Resnik   +5 more
doaj   +1 more source

Vascular Smooth Muscle-Specific Progerin Expression Accelerates Atherosclerosis and Death in a Mouse Model of Hutchinson-Gilford Progeria Syndrome [PDF]

open access: yes, 2018
Background: Progerin, an aberrant protein that accumulates with age, causes the rare genetic disease Hutchinson-Gilford progeria syndrome (HGPS). Patients who have HGPS exhibit ubiquitous progerin expression, accelerated aging and atherosclerosis, and ...
Andrés Manzano, María J.   +7 more
core   +4 more sources

Generation of three iPSC lines from dilated cardiomyopathy patients carrying a pathogenic LMNA variant

open access: yesStem Cell Research, 2022
LMNA-related dilated cardiomyopathy (DCM) is caused by pathogenic variants in LMNA and is characterized by left ventricular enlargement, reduced systolic function, and arrhythmia.
Chelsea Lee   +5 more
doaj   +1 more source

Molecular analysis of sarcomeric and non-sarcomeric genes in patients with hypertrophic cardiomyopathy. [PDF]

open access: yes, 2015
Background: Hypertrophic cardiomyopathy (HCM) is a common genetic heart disorder characterized by unexplained left ventricle hypertrophy associated with non-dilated ventricular chambers.
BOTTILLO, IRENE   +12 more
core   +1 more source

Irisin levels in LMNA-associated partial lipodystrophies [PDF]

open access: yesDiabetes & Metabolism, 2019
The adipo-myokine irisin regulates energy expenditure and fat metabolism. LMNA-associated familial partial lipodystrophy (FPLD2) comprises insulin resistance, muscle hypertrophy and lipoatrophy. The aim of this study was to investigate whether irisin could be a biomarker of FPLD2.This case control study included 19 FPLD2 subjects, 13 obese non-diabetic
Bensmaïne, F.   +11 more
openaire   +3 more sources

The ubiquitin E3/E4 ligase, UBE4A, fine-tunes protein ubiquitylation and accumulation at sites of DNA damage facilitating double-strand break repair [PDF]

open access: yes, 2018
Double-strand breaks (DSBs) are critical DNA lesions that robustly activate the elaborate DNA damage response (DDR) network. We identified a critical player in DDR fine-tuning - the E3/E4 ubiquitin ligase, UBE4A.
Baranes Bachar, Keren   +4 more
core   +1 more source

LMNA-related muscular dystrophy: Identification of variants in alternative genes and personalized clinical translation

open access: yesFrontiers in Genetics, 2023
Background: Laminopathies are caused by rare alterations in LMNA, leading to a wide clinical spectrum. Though muscular dystrophy begins at early ages, disease progression is different in each patient. We investigated variability in laminopathy phenotypes
Sergi Cesar   +68 more
doaj   +1 more source

Timing Mechanotransduction: Mechanically Dynamic Biomaterials Reveal the Temporal Hierarchy of YAP/TAZ Control Nodes

open access: yesAdvanced Science, EarlyView.
This work develops dynamically softening polyacrylamide hydrogels for time‐resolved imaging during continuous mechanical transitions. The study revealed that mechanotransduction is biphasic; YAP/TAZ inactivation is driven by early loss of the nucleocytoskeletal continuum connecting subnuclear adhesions, F‐actin, and the nuclear envelope, coupled with ...
Alessandro Gandin   +12 more
wiley   +1 more source

Lamin A Δexon9 mutation leads to telomere and chromatin defects but not genomic instability [PDF]

open access: yes, 2013
Over 300 mutations in the LMNA gene, encoding A-type lamins, are associated with 15 human degenerative disorders and premature aging syndromes. Although genomic instability seems to contribute to the pathophysiology of some laminopathies, there is ...
Das, Arindam   +8 more
core   +2 more sources

First Generation Proteolysis Targeting Chimeras (PROTACs) for the Treatment of Progeria

open access: yesAdvanced Science, EarlyView.
We report the first PROTACs designed to degrade progerin, introducing a novel therapeutic approach for progeria. The best compound, UCM‐18142, significantly reduces progerin levels and improves key disease phenotypes in patient‐derived cells and in the LmnaG609G/G609G mouse model, paving the way for new treatment strategies targeting the root cause of ...
Jon Macicior‐Michelena   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy